DNA Script closes $200 million Series C financing

Completion of second tranche set to accelerate commercial launch of revolutionary enzymatic DNA printing technology.

DNA Script, a pioneer in Enzymatic DNA Synthesis (EDS) for on-demand DNA printing, has announced the completion of its Series C financing, raising $200 million of new capital; with this latest financing, DNA Script has raised $315 million since the company was founded in 2014.

Longevity.Technology: Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. Nucleic acids are biopolymers made of nucleotides and are essential to all known forms of life. Oligonucleotides – often called oligos – are short single strands of synthetic DNA or RNA made up of nucleic acids.

Clearly DNA is important, but because they are small, oligos are the ideal starting point for many molecular and synthetic biological applications. Oligos are used in everything from genetic testing to forensic research and are also ideal in next-generation sequencing, which can deliver large amounts of genetic data in a short amount of time – vital for longevity research. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy.

Proceeds from this financing will be used to advance the SYNTAX Platform, DNA Script’s first commercial product powered by its proprietary EDS technology. SYNTAX enables the rapid printing of synthetic nucleic acids for genomics and molecular biology applications at the convenience of a lab bench. On-demand printing enables labs to iterate without waiting days or weeks to receive their genetic material from third-party service providers.

“We are thrilled to partner with this world-class group of investors, including new participants Baillie Gifford and T Rowe Price, who collectively share our vision to increase access to oligo manufacturing to accelerate the bio-revolution,” said DNA Script’s Co-founder and CEO Thomas Ybert. “SYNTAX is the first step toward creating a new paradigm for DNA and RNA synthesis. With the support of our investors, we look forward to continuing to advance this new paradigm to solve some of our largest challenges and advance human health [1].

[1] https://www.dnascript.com/press-releases/dna-script-closes-200-million-series-c-financing-with-completion-of-second-tranche/